- Report
- June 2026
- 197 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- June 2026
- 140 Pages
Global
From €5314EUR$5,850USD£4,588GBP
- Report
- October 2025
- 150 Pages
Global
From €4406EUR$4,850USD£3,804GBP
- Report
- April 2026
- 160 Pages
Global
From €3770EUR$4,150USD£3,255GBP
- Report
- May 2026
- 137 Pages
Global
From €4406EUR$4,850USD£3,804GBP
- Report
- November 2024
- 100 Pages
Global
From €5405EUR$5,950USD£4,666GBP
- Report
- April 2023
- 115 Pages
Global
From €4315EUR$4,750USD£3,725GBP
- Report
- December 2024
- 157 Pages
Global
From €2271EUR$2,500USD£1,961GBP
- Report
- May 2025
- 91 Pages
Global
From €3500EUR$4,127USD£3,127GBP
- Report
- October 2025
- 85 Pages
Kuwait
From €4406EUR$4,850USD£3,804GBP
The Anticoagulant Reversal Drug market is a subset of the Cardiovascular Drugs market. It is composed of drugs used to reverse the effects of anticoagulants, which are drugs used to prevent the formation of blood clots. These drugs are used to treat a variety of conditions, including deep vein thrombosis, pulmonary embolism, and atrial fibrillation. Anticoagulant reversal drugs are used to reduce the risk of bleeding in patients who have taken anticoagulants and require emergency surgery or other medical procedures.
Some companies in the Anticoagulant Reversal Drug market include Pfizer, Bristol-Myers Squibb, Merck, Sanofi, Bayer, and Novartis. Show Less Read more